Pilar Madrid-Lloret

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Journal: American journal of hematology

Published: June 23, 2026

Reply to: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.

Reply to: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 27, 2026

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica

Published: March 10, 2026

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Journal: Cancer

Published: November 03, 2025

The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia.

The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia.

Journal: Cancers

Published: October 20, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 13, 2025

Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.

Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.

Journal: Leukemia research

Published: September 22, 2025

Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study.

Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Cell Neoplasm: A PETHEMA Study.

Journal: Cancers

Published: July 09, 2025

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.

Journal: Haematologica

Published: June 26, 2025

CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?

CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?

Journal: Current oncology (Toronto, Ont.)

Published: May 05, 2025

Cardiotoxicity in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Cardiotoxicity in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia.

Journal: Cancers

Published: April 25, 2025

Feasible and Rapid Screening of IDH1/2 and FLT3-TKD2 Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia.

Feasible and Rapid Screening of IDH1/2 and FLT3-TKD2 Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia.

Journal: Diagnostics (Basel, Switzerland)

Published: March 17, 2025

Showing 1-12 of 21

Last Updated: 09/26/2026